S&P 500   3,852.36
DOW   32,920.46
QQQ   311.72
Retirement Plans in 2023: Choosing the Right Account
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Mullen Automotive Stock Gains Momentum On Positive News
Apple’s Earnings, Expectations and Surprises
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Cathie Woods' Ark Innovation ETF Set To Rebound in 2023?
The Bottom Is In For Meta Platforms, Volatility Is Not Over
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Exxon Mobil Could Gush To New Highs Very Soon 
Closing prices for crude oil, gold and other commodities
S&P 500   3,852.36
DOW   32,920.46
QQQ   311.72
Retirement Plans in 2023: Choosing the Right Account
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Mullen Automotive Stock Gains Momentum On Positive News
Apple’s Earnings, Expectations and Surprises
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Cathie Woods' Ark Innovation ETF Set To Rebound in 2023?
The Bottom Is In For Meta Platforms, Volatility Is Not Over
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Exxon Mobil Could Gush To New Highs Very Soon 
Closing prices for crude oil, gold and other commodities
S&P 500   3,852.36
DOW   32,920.46
QQQ   311.72
Retirement Plans in 2023: Choosing the Right Account
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Mullen Automotive Stock Gains Momentum On Positive News
Apple’s Earnings, Expectations and Surprises
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Cathie Woods' Ark Innovation ETF Set To Rebound in 2023?
The Bottom Is In For Meta Platforms, Volatility Is Not Over
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Exxon Mobil Could Gush To New Highs Very Soon 
Closing prices for crude oil, gold and other commodities
S&P 500   3,852.36
DOW   32,920.46
QQQ   311.72
Retirement Plans in 2023: Choosing the Right Account
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Mullen Automotive Stock Gains Momentum On Positive News
Apple’s Earnings, Expectations and Surprises
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Cathie Woods' Ark Innovation ETF Set To Rebound in 2023?
The Bottom Is In For Meta Platforms, Volatility Is Not Over
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Exxon Mobil Could Gush To New Highs Very Soon 
Closing prices for crude oil, gold and other commodities
NASDAQ:RVNC

Revance Therapeutics - RVNC Stock Forecast, Price & News

$35.27
+0.89 (+2.59%)
(As of 02/2/2023 12:00 AM ET)
Add
Compare
Today's Range
$34.39
$35.99
50-Day Range
$18.32
$35.27
52-Week Range
$11.27
$35.99
Volume
1.29 million shs
Average Volume
2.25 million shs
Market Capitalization
$2.90 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$39.64

Revance Therapeutics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.75 Rating Score
Upside/​Downside
12.4% Upside
$39.64 Price Target
Short Interest
Bearish
16.02% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.88
Upright™ Environmental Score
News Sentiment
0.59mentions of Revance Therapeutics in the last 14 days
Based on 14 Articles This Week
Insider Trading
Selling Shares
$131,519 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($4.26) to ($3.17) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.32 out of 5 stars

Medical Sector

306th out of 1,030 stocks

Pharmaceutical Preparations Industry

143rd out of 502 stocks

RVNC stock logo

About Revance Therapeutics (NASDAQ:RVNC) Stock

Revance Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development, manufacturing, and commercialization of novel botulinum toxin products for multiple aesthetic and therapeutic applications. The firm focuses on production of daxibotulinumtoxinA, a botulinum toxin, for aesthetic and therapeutic indications including facial wrinkles and muscle movement disorders. The company was founded by Jacob M. Waugh and L. Daniel Browne on August 10, 1999 and is headquartered in Nashville, TN.

Receive RVNC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Revance Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

RVNC Stock News Headlines

Revance Therapeutics (NASDAQ:RVNC) Raised to Hold at StockNews.com
Know Your Profit Potential BEFORE You Trade!
I’m Chuck Hughes, ten-time trading champion and author of the coveted e-book, “Options Trading Made Easy”, the strategy guide that will teach you to calculate your trade’s profit potential before you risk any capital. Click here for a free copy now! pixel
JPMorgan Chase Cuts Stake in Revance Therapeutics
Revance Therapeutics (NASDAQ:RVNC) PT Raised to $42.00
Revance Therapeutics (NASDAQ:RVNC) Price Target Raised to $26.00
Revance Therapeutics (NASDAQ:RVNC) PT Raised to $26.00
Know Your Profit Potential BEFORE You Trade!
I’m Chuck Hughes, ten-time trading champion and author of the coveted e-book, “Options Trading Made Easy”, the strategy guide that will teach you to calculate your trade’s profit potential before you risk any capital. Click here for a free copy now! pixel
What 4 Analyst Ratings Have To Say About Revance Therapeutics
Nanostics Announces New Member of Board of Directors
What 8 Analyst Ratings Have To Say About Revance Therapeutics
Revance Therapeutics's Earnings: A Preview
See More Headlines
Receive RVNC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Revance Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

RVNC Company Calendar

Last Earnings
11/08/2022
Today
2/02/2023
Next Earnings (Estimated)
2/27/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:RVNC
Employees
495
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$39.64
High Stock Price Forecast
$65.00
Low Stock Price Forecast
$24.00
Forecasted Upside/Downside
+12.4%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.75
Research Coverage
8 Analysts

Profitability

Net Income
$-281,310,000.00
Net Margins
-251.92%
Pretax Margin
-251.27%

Debt

Sales & Book Value

Annual Sales
$77.80 million
Book Value
$0.95 per share

Miscellaneous

Free Float
78,078,000
Market Cap
$2.90 billion
Optionable
Optionable
Beta
0.86

Key Executives

  • Mark J. FoleyMark J. Foley
    Chief Executive Officer & Director
  • Dustin S. Sjuts
    President
  • Tobin C. SchilkeTobin C. Schilke
    Chief Financial Officer
  • Azita Nejad
    Senior Vice President-Technical Operations
  • Roman G. Rubio
    Senior Vice President-Clinical Development













RVNC Stock - Frequently Asked Questions

Should I buy or sell Revance Therapeutics stock right now?

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Revance Therapeutics in the last year. There are currently 2 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" RVNC shares.
View RVNC analyst ratings
or view top-rated stocks.

What is Revance Therapeutics' stock price forecast for 2023?

8 analysts have issued 12-month price targets for Revance Therapeutics' stock. Their RVNC share price forecasts range from $24.00 to $65.00. On average, they anticipate the company's share price to reach $39.64 in the next twelve months. This suggests a possible upside of 12.4% from the stock's current price.
View analysts price targets for RVNC
or view top-rated stocks among Wall Street analysts.

How have RVNC shares performed in 2023?

Revance Therapeutics' stock was trading at $18.46 at the beginning of 2023. Since then, RVNC stock has increased by 91.1% and is now trading at $35.27.
View the best growth stocks for 2023 here
.

When is Revance Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, February 27th 2023.
View our RVNC earnings forecast
.

How were Revance Therapeutics' earnings last quarter?

Revance Therapeutics, Inc. (NASDAQ:RVNC) released its quarterly earnings data on Tuesday, November, 8th. The biopharmaceutical company reported ($1.17) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.85) by $0.32. The biopharmaceutical company had revenue of $29.02 million for the quarter, compared to analysts' expectations of $28.76 million. Revance Therapeutics had a negative trailing twelve-month return on equity of 461.54% and a negative net margin of 251.92%.

What is Mark Foley's approval rating as Revance Therapeutics' CEO?

7 employees have rated Revance Therapeutics Chief Executive Officer Mark Foley on Glassdoor.com. Mark Foley has an approval rating of 82% among the company's employees.

What other stocks do shareholders of Revance Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Revance Therapeutics investors own include Evolus (EOLS), Exelixis (EXEL), SCYNEXIS (SCYX), AbbVie (ABBV), Myovant Sciences (MYOV), Nektar Therapeutics (NKTR), Sorrento Therapeutics (SRNE), Bausch Health Companies (BHC), Catalyst Pharmaceuticals (CPRX) and Sangamo Therapeutics (SGMO).

What is Revance Therapeutics' stock symbol?

Revance Therapeutics trades on the NASDAQ under the ticker symbol "RVNC."

Who are Revance Therapeutics' major shareholders?

Revance Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include Allspring Global Investments Holdings LLC (1.33%), Rice Hall James & Associates LLC (1.06%), Assenagon Asset Management S.A. (0.23%), Moody Aldrich Partners LLC (0.14%), State of New Jersey Common Pension Fund D (0.12%) and Bfsg LLC (0.08%). Insiders that own company stock include Angus C Russell, Aubrey Rankin, Dwight Moxie, Mark J Foley and Tobin Schilke.
View institutional ownership trends
.

How do I buy shares of Revance Therapeutics?

Shares of RVNC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Revance Therapeutics' stock price today?

One share of RVNC stock can currently be purchased for approximately $35.27.

How much money does Revance Therapeutics make?

Revance Therapeutics (NASDAQ:RVNC) has a market capitalization of $2.90 billion and generates $77.80 million in revenue each year. The biopharmaceutical company earns $-281,310,000.00 in net income (profit) each year or ($3.92) on an earnings per share basis.

How many employees does Revance Therapeutics have?

The company employs 495 workers across the globe.

How can I contact Revance Therapeutics?

Revance Therapeutics' mailing address is 7555 GATEWAY BLVD., NEWARK CA, 94560. The official website for the company is www.revance.com. The biopharmaceutical company can be reached via phone at (615) 724-7755, via email at jherbert@revance.com, or via fax at 510-742-3401.

This page (NASDAQ:RVNC) was last updated on 2/3/2023 by MarketBeat.com Staff